| [1] |
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults[J]. Lancet, 2024, 403(10431):1027-1050.
|
| [2] |
Koskinas KC, Van Craenenbroeck EM, Antoniades C, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement[J]. Eur Heart J, 2024, 45(38):4063-4098.
|
| [3] |
Expert Consultation WHO. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies[J]. Lancet, 2004, 363(9403):157-163.
|
| [4] |
Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021[J]. Eur Heart J, 2022, 43(8):716-799.
|
| [5] |
GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health effects of overweight and obesity in 195 countries over 25 years[J]. N Engl J Med, 2017, 377(1):13-27.
|
| [6] |
Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2014, 384(9945):766-781.
|
| [7] |
Geserick M, Vogel M, Gausche R, et al. Acceleration of BMI in early childhood and risk of sustained obesity[J]. N Engl J Med, 2018, 379(14):1303-1312.
|
| [8] |
Katsoulis M, Lai AG, Diaz-Ordaz K, et al. Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records[J]. Lancet Diabetes Endocrinol, 2021, 9(10):681-694.
|
| [9] |
Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years[J]. N Engl J Med, 2007, 357(4):370-379.
|
| [10] |
Katzmarzyk PT, Pérusse L, Rao DC, et al. Familial risk of overweight and obesity in the Canadian population using the WHO/NIH criteria[J]. Obes Res, 2000, 8(2):194-197.
|
| [11] |
Blüher M. Obesity: global epidemiology and pathogenesis[J]. Nat Rev Endocrinol, 2019, 15(5):288-298.
|
| [12] |
Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies[J]. Lancet, 2011, 377(9771):1085-1095.
|
| [13] |
Wiklund P, Toss F, Weinehall L, et al. Abdominal and gynoid fat mass are associated with cardiovascular risk factors in men and women[J]. J Clin Endocrinol Metab, 2008, 93(11):4360-4366.
|
| [14] |
Britton KA, Fox CS. Ectopic fat depots and cardiovascular disease[J]. Circulation, 2011, 124(24):e837-e841.
|
| [15] |
Visseren F, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice[J]. Eur Heart J, 2021, 42(34):3227-3337.
|
| [16] |
Oikonomou EK, Williams MC, Kotanidis CP, et al. A novel machine learning-derived radiotranscriptomic signature of perivascular fat improves cardiac risk prediction using coronary CT angiography[J]. Eur Heart J, 2019, 40(43):3529-3543.
|
| [17] |
Frija-Masson J, Mullaert J, Vidal-Petiot E, et al. Accuracy of smart scales on weight and body composition: observational study[J]. JMIR Mhealth Uhealth, 2021, 9(4):e22487.
|
| [18] |
Antoniades C, Tousoulis D, Vavlukis M, et al. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers[J]. Eur Heart J, 2023, 44(38):3827-3844.
|
| [19] |
Iacobellis G. Epicardial adipose tissue in contemporary cardiology[J]. Nat Rev Cardiol, 2022, 19(9):593-606.
|
| [20] |
Polkinghorne MD, West HW, Antoniades C. Adipose tissue in cardiovascular disease: from basic science to clinical translation[J]. Annu Rev Physiol, 2024, 86:175-198.
|
| [21] |
Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes[J]. Eur Heart J, 2023, 44(39):4043-4140.
|
| [22] |
Cameron NA, Petito LC, McCabe M, et al. Quantifying the sex-race/ethnicity-specific burden of obesity on incident diabetes mellitus in the United States, 2001 to 2016: MESA and NHANES[J]. J Am Heart Assoc, 2021, 10(4):e018799.
|
| [23] |
Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial[J]. Lancet, 2018, 391(10120):541-551.
|
| [24] |
Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update[J]. Physiol Rev, 2013, 93(1):359-404.
|
| [25] |
Wildman RP, Mackey RH, Bostom A, et al. Measures of obesity are associated with vascular stiffness in young and older adults[J]. Hypertension, 2003, 42(4):468-473.
|
| [26] |
Hall JE. The kidney, hypertension, and obesity[J]. Hypertension, 2003, 41(3 Pt 2):625-33.
|
| [27] |
Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II[J]. Ann Intern Med, 2001, 134(1):1-11.
|
| [28] |
Després JP. Cardiovascular disease under the influence of excess visceral fat[J]. Crit Pathw Cardiol, 2007, 6(2):51-59.
|
| [29] |
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41(1):111-188.
|
| [30] |
Hasan B, Nayfeh T, Alzuabi M, et al. Weight loss and serum lipids in overweight and obese adults: a systematic review and meta-Analysis[J]. J Clin Endocrinol Metab, 2020, 105(12):dgaa673.
|
| [31] |
Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing[J]. J Am Coll Cardiol, 2008, 52(8):686-717.
|
| [32] |
Chirinos JA, Gurubhagavatula I, Teff K, et al. CPAP, weight loss, or both for obstructive sleep apnea[J]. N Engl J Med, 2014, 370(24):2265-2275.
|
| [33] |
Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis[J]. BMC Public Health, 2009, 9:88.
|
| [34] |
Battineni G, Sagaro GG, Chintalapudi N, et al. Impact of obesity-induced inflammation on cardiovascular diseases (CVD)[J]. Int J Mol Sci, 2021, 22(9):4798.
|
| [35] |
Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure[J]. N Engl J Med, 2002, 347(5):305-313.
|
| [36] |
Pandey A, LaMonte M, Klein L, et al. Relationship between physical activity, body mass index, and risk of heart failure[J]. J Am Coll Cardiol, 2017, 69(9):1129-1142.
|
| [37] |
黄峻. 中国心力衰竭流行病学特点和防治策略[J/OL]. 中华心脏与心律电子杂志, 2015 (2): 2-3.
|
| [38] |
Elkholey K, Papadimitriou L, Butler J, et al. Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction[J]. Am J Cardiol, 2021, 146:36-47.
|
| [39] |
Croteau D, Qin F, Chambers JM, et al. Differential effects of sacubitril/valsartan on diastolic function in mice with obesity-related metabolic heart disease[J]. JACC Basic Transl Sci, 2020, 5(9):916-927.
|
| [40] |
Nalliah CJ, Sanders P, Kottkamp H, et al. The role of obesity in atrial fibrillation[J]. Eur Heart J, 2016, 37(20):1565-1572.
|
| [41] |
Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J, 2024, 45(36):3314-3414.
|
| [42] |
Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism[J]. J Thromb Thrombolysis, 2016, 41(1):3-14.
|
| [43] |
Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis[J]. Circulation, 2008, 117(1):93-102.
|
| [44] |
Kushnir M, Choi Y, Eisenberg R, et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data[J]. Lancet Haematol, 2019, 6(7):e359-e365.
|
| [45] |
Perino AC, Fan J, Schmitt S, et al. Anticoagulation treatment and outcomes of venous thromboembolism by weight and body mass index: insights from the veterans health administration[J]. Circ Cardiovasc Qual Outcomes, 2021, 14(11):e008005.
|
| [46] |
Larsson SC, Wolk A, Håkansson N, et al. Overall and abdominal obesity and incident aortic valve stenosis: two prospective cohort studies[J]. Eur Heart J, 2017, 38(28):2192-2197.
|
| [47] |
Collaboration GBM, Di Angelantonio E, ShN B, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents[J]. Lancet, 2016, 388(10046):776-786.
|
| [48] |
Teramoto M, Yamagishi K, Cui R, et al. Body mass index and mortality from nonrheumatic aortic valve disease among Japanese men and women[J]. J Atheroscler Thromb, 2023, 30(2):150-159.
|
| [49] |
Patel E, Varghese JJ, Garg M, et al. Comparison of body mass index (four categories) to in-hospital outcomes in patients who underwent transcatheter aortic valve implantation[J]. Am J Cardiol, 2023, 192:190-195.
|
| [50] |
McInerney A, Tirado-Conte G, Rodes-Cabau J, et al. Impact of morbid obesity and obesity phenotype on outcomes after transcatheter aortic valve replacement[J]. J Am Heart Assoc, 2021, 10(12):e019051.
|
| [51] |
曾庆春, 许顶立. 钙化性主动脉瓣狭窄患者的心力衰竭治疗[J/OL]. 中华心脏与心律电子杂志, 2022, 10(3): 156.
|
| [52] |
Blüher M, Aras M, Aronne LJ, et al. New insights into the treatment of obesity[J]. Diabetes Obes Metab, 2023, 25(8):2058-2072.
|
| [53] |
Lugones-Sanchez C, Sanchez-Calavera MA, Repiso-Gento I, et al. Effectiveness of an mHealth intervention combining a smartphone App and smart band on body composition in an overweight and obese population: randomized controlled trial (EVIDENT 3 study)[J]. JMIR Mhealth Uhealth, 2020, 8(11):e21771.
|
| [54] |
Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity management in adults: a review[J]. JAMA, 2023, 330(20):2000-2015.
|
| [55] |
Ekelund U, Steene-Johannessen J, Brown WJ, et al. Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? a harmonised meta-analysis of data from more than 1 million men and women[J]. Lancet, 2016, 388(10051):1302-1310.
|
| [56] |
Oppert JM, Bellicha A, van Baak MA, et al. Exercise training in the management of overweight and obesity in adults: synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group[J]. Obes Rev, 2021, 22(Suppl 4):e13273.
|
| [57] |
Ge L, Sadeghirad B, Ball G, et al. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials[J]. BMJ, 2020, 369:m696.
|
| [58] |
Jay M, Gillespie C, Schlair S, et al. Physicians' use of the 5As in counseling obese patients: is the quality of counseling associated with patients' motivation and intention to lose weight? [J] BMC Health Serv Res, 2010, 10:159.
|
| [59] |
Wharton S, Lau D, Vallis M, et al. Obesity in adults: a clinical practice guideline[J]. CMAJ, 2020, 192(31):E875-E891.
|
| [60] |
Müller TD, Blüher M, Tschöp MH, et al. Anti-obesity drug discovery: advances and challenges[J]. Nat Rev Drug Discov, 2022, 21(3):201-223.
|
| [61] |
Chakhtoura M, Haber R, Ghezzawi M, et al. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation[J]. EClinicalMedicine, 2023, 58:101882.
|
| [62] |
Sattar N, Lee M, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials[J]. Lancet Diabetes Endocrinol, 2021, 9(10):653-662.
|
| [63] |
Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept[J]. Mol Metab, 2018, 18:3-14.
|
| [64] |
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes[J]. N Engl J Med, 2021, 385(6):503-515.
|
| [65] |
Cherla A, Renwick M, Stefanini G, et al. Cost-effectiveness of cardiovascular, obesity, and diabetes mellitus drugs: comparative analysis of the United States and England[J]. J Am Heart Assoc, 2020, 9(21):e018281.
|
| [66] |
Sharaiha RZ, Shikora S, White KP, et al. Summarizing consensus guidelines on obesity management: a joint, multidisciplinary venture of the International Federation for the Surgery of Obesity & Metabolic Disorders (IFSO) and World Gastroenterology Organisation (WGO)[J]. J Clin Gastroenterol, 2023, 57(10):967-976.
|
| [67] |
Abu Dayyeh BK, Bazerbachi F, Vargas EJ, et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial[J]. Lancet, 2022, 400(10350):441-451.
|
| [68] |
van Veldhuisen SL, Gorter TM, van Woerden G, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis[J]. Eur Heart J, 2022, 43(20):1955-1969.
|
| [69] |
Carlsson L, Sjöholm K, Jacobson P, et al. Life expectancy after bariatric surgery in the Swedish obese subjects study[J]. N Engl J Med, 2020, 383(16):1535-1543.
|